Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9AKVR)

Drug Name

2-APB Drug Info

Synonyms

2-aminoethoxydiphenyl borate; 2-aminoethoxydiphenylborane

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 1598
ChEBI ID: CHEBI:131184
CAS Number: CAS 524-95-8
TTD Drug ID: DM9AKVR

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Short transient receptor potential channel 5 (TRPC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 1358894	DM740BS	Depression	6A70-6A7Z	Phase 2	[18]
GFB-887	DM2IJWG	Diabetic nephropathy	GB61.Z	Phase 2	[19]
daidzein	DMRFTJX	Discovery agent	N.A.	Investigative	[20]
lysophosphatidylcholine	DMOGFVH	Discovery agent	N.A.	Investigative	[20]
KB-R7943	DMMD5W3	Discovery agent	N.A.	Investigative	[21]
BTP2	DMNM63G	Discovery agent	N.A.	Investigative	[20]
bromoenol lactone	DMKQ0CA	Discovery agent	N.A.	Investigative	[22]
ML204	DM15YL0	Discovery agent	N.A.	Investigative	[23]
(-)-englerin A	DMPQBWY	Discovery agent	N.A.	Investigative	[24]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Drug(s) Targeting Transient receptor potential cation channel V6 (TRPV6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SOR-C13	DMBKL6O	Alzheimer disease	8A20	Phase 1	[25]
------------------------------------------------------------------------------------

Drug(s) Targeting Short transient receptor potential channel 7 (TRPC7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
OAG	DMOP8IJ	Discovery agent	N.A.	Investigative	[26]
------------------------------------------------------------------------------------

Drug(s) Targeting Long transient receptor potential channel 7 (TRPM7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PIP2	DMOZV7N	Discovery agent	N.A.	Investigative	[27]
carvacrol	DMINM2D	Discovery agent	N.A.	Investigative	[28]
waixenicin A	DMB6H35	Discovery agent	N.A.	Investigative	[29]
------------------------------------------------------------------------------------

Drug(s) Targeting Short transient receptor potential channel 2 (TRPC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
OAG	DMOP8IJ	Discovery agent	N.A.	Investigative	[8]
SAG	DMHOG7W	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------

Drug(s) Targeting Short transient receptor potential channel 3 (TRPC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACAA	DMACYPW	Discovery agent	N.A.	Investigative	[30]
OAG	DMOP8IJ	Discovery agent	N.A.	Investigative	[31]
KB-R7943	DMMD5W3	Discovery agent	N.A.	Investigative	[30]
BTP2	DMNM63G	Discovery agent	N.A.	Investigative	[32]
Pyr3	DM3VNYQ	Discovery agent	N.A.	Investigative	[33]
------------------------------------------------------------------------------------

Drug(s) Targeting Long transient receptor potential channel 8 (TRPM8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[34]
D-3263	DM7V2OM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[35]
PF-05105679	DM4QPT0	Pain	MG30-MG3Z	Phase 1	[36]
ACAA	DMACYPW	Discovery agent	N.A.	Investigative	[37]
5-METHOXYTRYPTAMINE	DMARCKD	Discovery agent	N.A.	Investigative	[38]
icilin	DMYVOL9	Discovery agent	N.A.	Investigative	[39]
2-(5-fluoro-1H-indol-3-yl)ethanamine	DMHW5FT	Discovery agent	N.A.	Investigative	[38]
NADA	DM3ORGM	Discovery agent	N.A.	Investigative	[37]
2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine	DMD2QVO	Discovery agent	N.A.	Investigative	[38]
linalool	DMGZQ5P	Discovery agent	N.A.	Investigative	[40]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Transient receptor potential cation channel V3 (TRPV3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR292833	DM63QY0	Pain	MG30-MG3Z	Phase 2	[41]
diphenylboronic anhydride	DMRQZTS	Discovery agent	N.A.	Investigative	[42]
citral	DM53ZGY	Discovery agent	N.A.	Investigative	[43]
aspirin-triggered resolvin D1	DMOP941	Discovery agent	N.A.	Investigative	[44]
carvacrol	DMINM2D	Discovery agent	N.A.	Investigative	[45]
cinnamaldehyde	DMZDUXG	Discovery agent	N.A.	Investigative	[46]
diphenyltetrahydrofuran	DMK8T61	Discovery agent	N.A.	Investigative	[42]
carveol	DMGIZ5U	Discovery agent	N.A.	Investigative	[47]
dihydrocarveol	DMS4U68	Discovery agent	N.A.	Investigative	[47]
tetrahydrocannabivarin	DMDY1MZ	Discovery agent	N.A.	Investigative	[48]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Long transient receptor potential channel 3 (TRPM3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
sphinganine	DM9ZBLE	Discovery agent	N.A.	Investigative	[49]
epipregnanolone sulphate	DMW271Q	Discovery agent	N.A.	Investigative	[50]
NN-dimethyl-D-erythrosphingosine	DMSYOHD	Discovery agent	N.A.	Investigative	[49]
------------------------------------------------------------------------------------

Drug(s) Targeting Long transient receptor potential channel 2 (TRPM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACAA	DMACYPW	Discovery agent	N.A.	Investigative	[51]
NAADP	DM51DW6	Discovery agent	N.A.	Investigative	[52]
OAADPR	DM458IH	Discovery agent	N.A.	Investigative	[53]
ADP ribose	DMQ1F7J	Discovery agent	N.A.	Investigative	[54]
GEA 3162	DMBGWEK	Discovery agent	N.A.	Investigative	[55]
cADPR	DMLKZQH	Discovery agent	N.A.	Investigative	[52]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Targeting Short transient receptor potential channel 6 (TRPC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
lysophosphatidylcholine	DMOGFVH	Discovery agent	N.A.	Investigative	[11]
ACAA	DMACYPW	Discovery agent	N.A.	Investigative	[11]
OAG	DMOP8IJ	Discovery agent	N.A.	Investigative	[31]
KB-R7943	DMMD5W3	Discovery agent	N.A.	Investigative	[11]
flufenamate	DMN8AP0	Discovery agent	N.A.	Investigative	[11]
SAG	DMHOG7W	Discovery agent	N.A.	Investigative	[31]
ML9	DMP13VE	Discovery agent	N.A.	Investigative	[11]
hyp 9	DM0U8IV	Discovery agent	N.A.	Investigative	[56]
SLG	DMEBPCO	Discovery agent	N.A.	Investigative	[31]
20-HETE	DM5BAJ9	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Transient receptor potential cation channel V2 (TRPV2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[14]
lysophosphatidylcholine	DMOGFVH	Discovery agent	N.A.	Investigative	[57]
diphenylboronic anhydride	DMRQZTS	Discovery agent	N.A.	Investigative	[14]
lysophosphatidylinositol	DMETM3R	Discovery agent	N.A.	Investigative	[57]
citral	DM53ZGY	Discovery agent	N.A.	Investigative	[43]
cannabinol	DMM6A7P	Discovery agent	N.A.	Investigative	[58]
TRIM	DMNHU4M	Discovery agent	N.A.	Investigative	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Drug(s) Targeting Transient receptor potential cation channel V1 (TRPV1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[59]
CNTX-4975	DMB4JPG	Knee osteoarthritis	FA01	Phase 3	[60]
XEN-D0501	DMG7PDY	Overactive bladder	GC50.0	Phase 2	[61]
Resiniferatoxin	DMP62L5	Neuropathic pain	8E43.0	Phase 2	[62]
PAC-14028	DM3816P	Atopic dermatitis	EA80	Phase 2	[63]
GRC-15300	DMWXJSZ	Pain	MG30-MG3Z	Phase 2	[64]
DWP-05195	DMQKU2F	Neuropathic pain	8E43.0	Phase 2	[65]
SB-705498	DMRYHWI	Rhinitis	FA20	Phase 2	[66]
GRC-6211	DMZ0D3V	Asthma	CA23	Phase 1	[67]
ABT-102	DMJFWPR	Chronic pain	MG30	Phase 1	[66]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Short transient receptor potential channel 4 (TRPC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 1358894	DM740BS	Depression	6A70-6A7Z	Phase 2	[18]
ML204	DM15YL0	Discovery agent	N.A.	Investigative	[23]
(-)-englerin A	DMPQBWY	Discovery agent	N.A.	Investigative	[24]
------------------------------------------------------------------------------------

Drug(s) Affected By Procathepsin L (CTSL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[68]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[70]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[71]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[72]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[73]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[74]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[75]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[70]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[76]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[77]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[78]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[79]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[82]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[83]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[84]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[85]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[86]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Long transient receptor potential channel 2 (TRPM2)	TTEBMN7	TRPM2_HUMAN	Blocker (channel blocker)	[2]
Long transient receptor potential channel 3 (TRPM3)	TTO3TD8	TRPM3_HUMAN	Inhibitor (gating inhibitor)	[3]
Long transient receptor potential channel 6 (TRPM6)	TTV76RD	TRPM6_HUMAN	Activator	[4]
Long transient receptor potential channel 7 (TRPM7)	TTFPVZO	TRPM7_HUMAN	Activator	[5]
Long transient receptor potential channel 8 (TRPM8)	TTXDKTO	TRPM8_HUMAN	Blocker (channel blocker)	[6]
Short transient receptor potential channel 1 (TRPC1)	TTA76X0	TRPC1_HUMAN	Blocker (channel blocker)	[7]
Short transient receptor potential channel 2 (TRPC2)	TTSJ9E7	Q3C1U7_HUMAN	Blocker (channel blocker)	[8]
Short transient receptor potential channel 3 (TRPC3)	TTNVC34	TRPC3_HUMAN	Blocker (channel blocker)	[9]
Short transient receptor potential channel 4 (TRPC4)	TTX0H5W	TRPC4_HUMAN	Blocker (channel blocker)	[10]
Short transient receptor potential channel 5 (TRPC5)	TT32NQ1	TRPC5_HUMAN	Blocker (channel blocker)	[3]
Short transient receptor potential channel 6 (TRPC6)	TTRBT3W	TRPC6_HUMAN	Blocker (channel blocker)	[11]
Short transient receptor potential channel 7 (TRPC7)	TT06GRA	TRPC7_HUMAN	Blocker (channel blocker)	[12]
Transient receptor potential cation channel V1 (TRPV1)	TTMI6F5	TRPV1_HUMAN	Activator	[13]
Transient receptor potential cation channel V2 (TRPV2)	TTBECWA	TRPV2_HUMAN	Activator	[14]
Transient receptor potential cation channel V3 (TRPV3)	TT946IA	TRPV3_HUMAN	Activator	[15]
Transient receptor potential cation channel V6 (TRPV6)	TTBK14N	TRPV6_HUMAN	Activator	[16]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B)	OTUYHB84	MLP3B_HUMAN	Gene/Protein Processing	[17]
Procathepsin L (CTSL)	OTYTUW29	CATL1_HUMAN	Protein Interaction/Cellular Processes	[17]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2433).
2	Inhibition of the transient receptor potential cation channel TRPM2 by 2-aminoethoxydiphenyl borate (2-APB). Br J Pharmacol. 2008 Mar;153(6):1324-30.
3	Block of TRPC5 channels by 2-aminoethoxydiphenyl borate: a differential, extracellular and voltage-dependent effect. Br J Pharmacol. 2005 Jun;145(4):405-14.
4	Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. J Gen Physiol. 2006 May;127(5):525-37.
5	LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability. Nature. 2001 May 31;411(6837):590-5.
6	Effects of antagonists and heat on TRPM8 channel currents in dorsal root ganglion neuron activated by nociceptive cold stress and menthol. Neurochem Res. 2012 Feb;37(2):314-20.
7	TRPC1 and TRPC5 form a novel cation channel in mammalian brain. Neuron. 2001 Mar;29(3):645-55.
8	A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction. Neuron. 2003 Oct 30;40(3):551-61.
9	Mechanism of inhibition of TRPC cation channels by 2-aminoethoxydiphenylborane. Mol Pharmacol. 2005 Sep;68(3):758-62.
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 489).
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491).
12	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 492).
13	2-aminoethoxydiphenyl borate is a common activator of TRPV1, TRPV2, and TRPV3. J Biol Chem. 2004 Aug 20;279(34):35741-8.
14	Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxy... Mol Pharmacol. 2007 Nov;72(5):1258-68.
15	2-aminoethoxydiphenyl borate activates and sensitizes the heat-gated ion channel TRPV3. J Neurosci. 2004 Jun 2;24(22):5177-82.
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 512).
17	The relationship between Cd-induced autophagy and lysosomal activation in WRL-68 cells. J Appl Toxicol. 2015 Nov;35(11):1398-405. doi: 10.1002/jat.3114. Epub 2015 Jan 29.
18	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
19	Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. Kidney Int Rep. 2021 Jul 23;6(10):2575-2584.
20	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 490).
21	The Na+/Ca2+ exchange inhibitor KB-R7943 potently blocks TRPC channels. Biochem Biophys Res Commun. 2007 Sep 14;361(1):230-6.
22	Bromoenol lactone inhibits voltage-gated Ca2+ and transient receptor potential canonical channels. J Pharmacol Exp Ther. 2011 Nov;339(2):329-40.
23	Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. J Biol Chem. 2011 Sep 23;286(38):33436-46.
24	(-)-Englerin is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew Chem Int Ed Engl. 2015 Mar 16;54(12):3787-91.
25	In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin. PLoS One. 2013;8(3):e58866.
26	Molecular and functional characterization of a novel mouse transient receptor potential protein homologue TRP7. Ca(2+)-permeable cation channel that is constitutively activated and enhanced by stimulation of G protein-coupled receptor. J Biol Chem. 1999 Sep 24;274(39):27359-70.
27	The TRPM7 channel is inactivated by PIP(2) hydrolysis. Nat Cell Biol. 2002 May;4(5):329-36.
28	Carvacrol is a novel inhibitor of Drosophila TRPL and mammalian TRPM7 channels. Cell Calcium. 2009 Mar;45(3):300-9.
29	Waixenicin A inhibits cell proliferation through magnesium-dependent block of transient receptor potential melastatin 7 (TRPM7) channels. J Biol Chem. 2011 Nov 11;286(45):39328-35.
30	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 488).
31	Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature. 1999 Jan 21;397(6716):259-63.
32	A functional link between store-operated and TRPC channels revealed by the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2. J Biol Chem. 2005 Mar 25;280(12):10997-1006.
33	Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5400-5.
34	TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10.
35	Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009 Spring; 11(2): 82-107.
36	Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans. J Pharmacol Exp Ther. 2014 Nov;351(2):259-69.
37	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 500).
38	5-benzyloxytryptamine as an antagonist of TRPM8. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7076-9.
39	Evolution of thermal response properties in a cold-activated TRP channel. PLoS One. 2009 May 29;4(5):e5741.
40	Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
41	Pharmacological profiling of the TRPV3 channel in recombinant and native assays. Br J Pharmacol. 2014 May;171(10):2631-44.
42	Biphasic currents evoked by chemical or thermal activation of the heat-gated ion channel, TRPV3. J Biol Chem. 2005 Apr 22;280(16):15928-41.
43	Citral sensing by Transient [corrected] receptor potential channels in dorsal root ganglion neurons. PLoS One. 2008 May 7;3(5):e2082.
44	17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception. Br J Pharmacol. 2012 Feb;165(3):683-92.
45	Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. Nat Neurosci. 2006 May;9(5):628-35.
46	More than cool: promiscuous relationships of menthol and other sensory compounds. Mol Cell Neurosci. 2006 Aug;32(4):335-43.
47	Monoterpenoid agonists of TRPV3. Br J Pharmacol. 2007 Jun;151(4):530-40.
48	Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf). 2012 Feb;204(2):255-66.
49	Activation of the melastatin-related cation channel TRPM3 by D-erythro-sphingosine [corrected]. Mol Pharmacol. 2005 Mar;67(3):798-805.
50	Cis-isomerism and other chemical requirements of steroidal agonists and partial agonists acting at TRPM3 channels. Br J Pharmacol. 2010 Sep;161(2):430-41.
51	Inhibition of TRPM2 cation channels by N-(p-amylcinnamoyl)anthranilic acid. Br J Pharmacol. 2006 Jun;148(3):264-73.
52	Nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose regulate TRPM2 channels in T lymphocytes. FASEB J. 2006 May;20(7):962-4.
53	Metabolite of SIR2 reaction modulates TRPM2 ion channel. J Biol Chem. 2006 May 19;281(20):14057-65.
54	ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology. Nature. 2001 May 31;411(6837):595-9.
55	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 494).
56	Simple 2,4-diacylphloroglucinols as classic transient receptor potential-6 activators--identification of a novel pharmacophore. Mol Pharmacol. 2010 Mar;77(3):368-77.
57	Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta. 2009 Mar;1793(3):528-39.
58	TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci. 2008 Jun 11;28(24):6231-8.
59	Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71.
60	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
61	An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921-31.
62	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
63	Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6.
64	The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest. 2010 November 1; 120(11): 3753-3759.
65	TRPV1 Antagonists as Analgesic Agents. The Open Pain Journal, 2013, 6, (Suppl 1: M11), 108-118 .
66	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
67	GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol. 2009 Jan;181(1):379-86.
68	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
69	Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
70	Phenytoin and cyclosporin A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts. J Periodontol. 2000 Jun;71(6):955-60. doi: 10.1902/jop.2000.71.6.955.
71	Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
72	Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
73	The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing human melanoma cells to starvation- and chemotherapy-induced cell death. Autophagy. 2013 Dec;9(12):2087-102. doi: 10.4161/auto.26506. Epub 2013 Oct 8.
74	A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
75	A role for the autophagy regulator Transcription Factor EB in amiodarone-induced phospholipidosis. Biochem Pharmacol. 2015 Jun 1;95(3):201-9. doi: 10.1016/j.bcp.2015.03.017. Epub 2015 Apr 13.
76	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
77	Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
78	Repression of Kisspeptin1 weakens hydrogen peroxide-caused injury in HTR8 cells via adjusting PI3K/AKT/mTOR pathway. J Biochem Mol Toxicol. 2020 May;34(5):e22461. doi: 10.1002/jbt.22461. Epub 2020 Feb 11.
79	Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
80	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
81	Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy. Oxid Med Cell Longev. 2018 Mar 18;2018:1482795. doi: 10.1155/2018/1482795. eCollection 2018.
82	Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
83	Inhibitory effect of PXR on ammonia-induced hepatocyte autophagy via P53. Toxicol Lett. 2018 Oct 1;295:153-161. doi: 10.1016/j.toxlet.2018.06.1066. Epub 2018 Jun 14.
84	Arsenic trioxide induces autophagic cell death in osteosarcoma cells via the ROS-TFEB signaling pathway. Biochem Biophys Res Commun. 2018 Jan 29;496(1):167-175. doi: 10.1016/j.bbrc.2018.01.018. Epub 2018 Jan 4.
85	TNF enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17.
86	Hydroquinone-induced endoplasmic reticulum stress affects TK6 cell autophagy and apoptosis via ATF6-mTOR. Environ Toxicol. 2023 Aug;38(8):1874-1890. doi: 10.1002/tox.23814. Epub 2023 May 6.